Marie Hudson1, Hugues Richard, Louise Pilote. 1. Division of Clinical Epidemiology, Research Institute of McGill University Health Center, 1650 Cedar Avenue, Montreal, QC, H3G 1A4 Canada.
Abstract
OBJECTIVES: To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. DESIGN: Population based retrospective cohort study. SETTING: Databases of hospital discharge summaries and prescription drug claims in Quebec. PARTICIPANTS: 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or an NSAID after an index admission for congestive heart failure between April 2000 and March 2002. MAIN OUTCOME MEASURES: Time to all cause death and recurrent congestive heart failure, combined and separately. RESULTS: The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib. CONCLUSIONS: Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.
OBJECTIVES: To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. DESIGN: Population based retrospective cohort study. SETTING: Databases of hospital discharge summaries and prescription drug claims in Quebec. PARTICIPANTS: 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or an NSAID after an index admission for congestive heart failure between April 2000 and March 2002. MAIN OUTCOME MEASURES: Time to all cause death and recurrent congestive heart failure, combined and separately. RESULTS: The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib. CONCLUSIONS:Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.
Authors: Sean Z Zhao; Thomas A Burke; Andrew Whelton; Heather von Allmen; Scott C Henderson Journal: Am J Manag Care Date: 2002-10 Impact factor: 2.229
Authors: Zhibing Zhang; Roberta Vezza; Theodore Plappert; Peter McNamara; John A Lawson; Sandra Austin; Domenico Praticò; Martin St-John Sutton; Garret A FitzGerald Journal: Circ Res Date: 2003-04-17 Impact factor: 17.367
Authors: Muhammad Mamdani; Paula Rochon; David N Juurlink; Geoffrey M Anderson; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis Journal: Arch Intern Med Date: 2003-02-24
Authors: Muhammad Mamdani; David N Juurlink; Douglas S Lee; Paula A Rochon; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis; Therese A Stukel Journal: Lancet Date: 2004-05-29 Impact factor: 79.321
Authors: Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights Journal: Br J Clin Pharmacol Date: 2010-06 Impact factor: 4.335
Authors: Peter B Anning; Barbara Coles; Jonathan Morton; Haibin Wang; Jashim Uddin; Jason D Morrow; Sudhansu K Dey; Lawrence J Marnett; Valerie B O'Donnell Journal: Blood Date: 2006-08-24 Impact factor: 22.113
Authors: F P Luyten; P Geusens; M Malaise; L De Clerck; R Westhovens; F Raeman; D Vander Mijnsbrugge; L Mathy; J P Hauzeur; F De Keyser; F Van den Bosch Journal: Ann Rheum Dis Date: 2006-06-30 Impact factor: 19.103